The novel coronavirus conjures up such images of healthcare warriors inserting long pipe-like sticks with soft brushes up a nose and twirling it around for a few seconds. An extremely good specimen is apparently collected only when the swab goes far back for cells and fluids from the entire passageway that connects the base of the nose to the back of the throat.

But unlike an RT-PCR test that studies the genetic disposition of the novel coronavirus from nasal samples, the Antigen test detects the presence of the nucleocapsid protein which is part of the SARS-CoV-2 virus that causes the coronavirus disease (COVID). Not only is the Antigen test less sensitive and more specific, but it also most certainly rules out the asymptomatic and symptomatic carriers of COVID-19 in a quicker and cost-effective way.

While a positive Antigen test may be informative, a negative result would need to be confirmed by the more sensitive nucleic acid test and thus, it becomes imperative for laboratories and hospitals to ensure that all symptomatic negative patients be referred to a real-time RT-PCR test for COVID-19.

The Indian Council of Medical Research (ICMR) has validated and approved Trivitron Healthcare’s flagship COVID-19 Rapid Testing Antigen Kit – Biocard Pro COVID-19 Rapid Antigen – and recommends the test as a point-of-care diagnostic assay for testing, in combination with the gold standard RT-PCR test. These kits claim to provide accurate results in 7 to 10 minutes.

Biocard Pro COVID-19 Rapid Antigen

Biocardpro COVID-19 Antigen kit is a chromatographic immunoassay for the qualitative detection of COVID-19 specific antigen. With the help of a nasal sample, it collects fluid samples, and produces results in minutes. Biocard Pro COVID-19 Rapid Antigen provides test results rapidly, at cost-effective rates, and can be more amenable to point-of-care use, and therefore more suitable for testing in community and remote regions.

As these tests are faster and less expensive than other popularly known PCR tests, Antigen tests may be more practical to use for large number of people. The Biocardpro COVID-19 Antigen kit is one of the few rapid antigen kits to yield satisfactory results, manufactured at Trivitron’s Chennai manufacturing facility at the rate of around 4.5-5 million tests per month. The company plans to distribute these kits to various government entities and private laboratories through various marketing channels.

As India touches the 7.2 million mark for Covid-19 caseloads, arresting the surge in case numbers and access to COVID-19 testing still remains a huge challenge. In our effort to increase the rapid outreach of point-of-care diagnostic testing, Antigen tests will remain as one of the most important tools that saves valuable time, cost and lives.

Mr. Rajesh Patel
CEO – IVD India
Trivitron Healthcare

The post The Power of Antigen Tests appeared first on Health Vision.

In the global uncertainty of COVID-19, healthcare industry leader- Trivitron Healthcare, counts for the continuity of services & solutions for COVID-19. Responding to the honorable Prime Minister Modi’s call for ‘Vocal for Local’, Trivitron Healthcare as a leading domestic health technology company, is pleased to announce the launch of a full suite of indigenously developed COVID-19 Testing products, as the organization’s contribution towards Atmanirbhar (self-reliant) Bharat.

Trivitron Healthcare offers a comprehensive range of ICMR approved COVID-19 solutions including RT-PCR Tests (COVIDsure & COVID sure Pro), RNA Extraction kits (RNAsure), Viral Transport Media (ViSure), Total Antibody ELISA Test (COVIDscreen Plus) and ELISA IgG (COVID Kavach IgG) testing kits for Covid-19. Realizing the enormous need of testing kits in the domestic market, to address this, the organization has indigenously designed & developed, and had started large scale manufacturing for COVID-19 RT‑PCR test kits, RNA Extraction kits, Viral Transport Media, ELISA Antibody Tests, and will soon be launching Rapid POC Tests as well, for the Indian market.

Trivitron has been tracking the alarming spread of COVID-19, since the world media started reporting its devastating impact on China. Trivitron as a torchbearer of the ‘Make in India’ initiative and supporting the leadership’s call for a self-reliant nation, has decided to accelerate and enhance products and countermeasures to combat the spread of COVID‑19 in India. By March 2020, efforts were upscaled to indigenously create required solutions, without losing time, within the given constraints and available resources, at Trivitron’s state-of-the-art facilities – Trivitron Medical Technology Park, Chennai and AMTZ, Vishakhapatnam.

As a result of this approach, Trivitron is the only Indian organization that is ready with a complete portfolio of indigenously developed technologies which can be utilized for combating COVID-19 and to fulfill the low-cost testing needs for the country, and with indigenously manufactured Comprehensive COVID-19 testing solutions, ensuring the best suppliers across the world.

“Trivitron is committed to manufacturer cost-effective and globally accepted high-quality kits, and other COVID-19 solutions. We have been focused on making world-class Made-in-India medical technology solutions for domestic and global markets. The current situation of COVID-19 pandemic demanded innovation in developing indigenous and economical testing kits for the Indian market and we have responded to this. We have a complete range of COVID testing portfolio which will enable scaling up of current testing needs of the Indian & International Healthcare Ecosystem.’’ says, Dr. GSK Velu, Chairman and Managing Director, Trivitron Healthcare.

Also Read: GLOBAL ECONOMIC SLOWDOWN, OPPORTUNITY FOR HEALTHCARE INDUSTRY

The post Trivitron responds to PM Modi’s call for ‘Atmanirbhar Bharat’ appeared first on Health Vision.

Ace health technology organization, Trivitron healthcare has introduced COVIDscreen Plus, an indigenously developed & manufactured ELISA test kit for the diagnosis of COVID-19 infection. The kit is designed for the qualitative detection of SARS-CoV-2 IgG, IgM and IgA antibodies. COVID screen plus is approved and validated by the Indian Council of Medical Research (ICMR). COVID screen plus guarantees high diagnostic value as it offers 100% sensitivity and 99% specificity. The kit is based on the double antigen sandwich ELISA technique, and makes use of blood serum/blood plasma as sample.

The Elisa test kit, though needs to be handled by a trained or an experienced professional, offers ease-of-use to facilitate swift action and hassle-free use. The Elisa test kit features world-class quality and comes with color-coded reagents so that it can be easily identified by the laboratory technician.This feature not only saves time but also nullifies the possibility of operational errors.

COVID screen Plus uses high purity reagents with enhanced reactivity which considerably lowers its incubation time and offers prompt results. This Elisa test kit is intended to play a pivotal role in mass screening of COVID-19 by all kinds of laboratories in the country. The affordable price per test of COVID screen Plus ELISA test kit will ensure greater acceptance, accessibility, and shall facilitate testing for one and all. “COVIDscreen Plus is the latest entrant in COVID diagnostic kits and has been developed under the Make in India initiative. The Elisa test kit offers high diagnostics valuethrough enhanced sensitivity & specificity and is affordable as compared to otherCOVID RT PCR diagnostickits available in the market.” says  Mr. Rajesh Patel, CEO-IVD (India) Trivitron Healthcare.

In view of the ICMR’s latest decision of allowing COVID-19 testing in all the laboratories, Trivitron’s COVID screen Plus ELISA test kit comes with unique ‘break apart’ wells that offers flexibility so that it can be used by large, medium &small-scale laboratories. Additionally, COVID screen Plus is packed in convenient pack size (96 tests per pack) and has higher shelf life of 15 months (at specified storage conditions) that makes it an ideal testing kit for hospitals, in-house healthcare settings, clinics & laboratories, and it is perfectly fit for inter-state, &overseas transportation.

The post Trivitron introduces COVIDscreen Plus ELISA test kit appeared first on Health Vision.

New Delhi, 11th July 2020: Trivitron Healthcare Private Limited, a leading medical device company providing affordable healthcare solutions to the healthcare industry, has announced the appointment of Mr. Rajesh Patel as Chief Executive Officer of In-Vitro Diagnostics [IVD], India business.

Mr. Patel is an experienced professional with around 29 years in the areas of sales, marketing & business development in healthcare segment. He has held leadership role in global and Indian healthcare companies and has a rich and diverse experience in pharmaceuticals, clinical research and IVD/Medical Devices segment.

Commenting on his appointment, Mr. Rajesh Patel, CEO, {IVD- India}, TrivitronHealthcare said, “I am excited by the opportunity to build on the great foundation and momentum achieved by the Trivitron Group and lead the company through the next stage of its strategic development. I am committed to ensure that we not only stay at the forefront in this space but we continue to innovate and lead the market.”

Dr GSK Velu, Chairman and Managing Director, Trivitron Healthcare said. “In his new role, Mr. Patel will be at the helm of the company’s IVD business growth and expansion plans. His enthusiastic approach, progressive effort will provide a new leadership to IVD team and will help the division to reach a new milestone. We look forward to an exciting journey along with him and wish him all the success.’’

Expressing her delight on the appointment, Ms. Chandra Ganjoo, Executive Director, Group CPO & Head Corporate Communications, added,“Mr.Rajesh’s strategic leadership, operational excellence expertise in healthcare and passion for innovation will be great assets to us as we grow in the coming years. Mr. Patel will be playing a significant role in reshaping the IVD business and the Trivitron group’s international footprint.”

The post Trivitron healthcare appoints Mr. Rajesh Patel as CEO of In-Vitro diagnostics appeared first on Health Vision.

New Delhi – 16^th March 2020 : Trivitron Healthcare’s Imaging Division, Kiran Medical Systems has achieved a significant milestone in Radiation Protection. All components that can come in contact with the skin, the Fabric, Thread and Edge Binding Fabric used in Kiran’s Radiation Protection Products have been tested and proven to be compliant with International Biocompatibility Quality standards ISO10993-1:2018, ISO 10993-5:2009 (E) & ISO 10993-10:2010(E). Kiran Radiation Protection Aprons are non-sensitizer, non-cytotoxic and non-irritant.

Sensitization (Type IV hypersensitivity reaction) and Skin irritation are key toxicity endpoints to assess the biocompatibility of medical devices. Guinea pig maximization test is the sensitive method to determine the sensitization potential of medical devices, both in terms of induction and elicitation. An assessment is made to know the Skin irritation potential of the material under test to produce dermal irritation in rabbits following topical application.

Mr. Satyaki Banerjee, CEO – Medical Imaging, Trivitron Healthcare, said, “Kiran being a Global Leader in Radiation Protection, is committed to continuous innovation and deliver the absolute best to its customers across the globe with products that set the benchmark standard in terms of scientific differentiation and compliance to International Regulatory norms. Our radiation protection products have evolved over the years with Satin Touch Fabric with Nanotech coating, multi-layer microparticle core materials, magnetic closure systems and now biocompatibility are some of the world’s first that Kiran developed for its customers.”

Kiran Satin Touch Fabric was tested successfully for cytotoxicity, skin irritation, and skin sensitization as per ISO’s biocompatibility standard guidelines which provide the framework for determining the appropriate biocompatibility steps for planning a biological evaluation. Kiran Satin Touch fabric is infused with Zinc Pirithione (ZNP) which possesses anti-microbial properties. Radiation protection aprons, accessories and protective gears crafted from Satin Touch offer best fit, comfort and feel and is available in a variety of colour shades.

Trivitron’s Kiran portfolio of radiology products include a comprehensive range of Radiation Protection Products, Ultisys range of Mobile & Fixed Digital Radiography systems, Infinity and Elite series surgical C-Arm systems featuring Flat Panel Detector technology, Felicia Digital Mammography, SonoRad V9 & V10 Color Doppler systems, Contrast Media, Anti-scatter X-ray grids and a wide range of Imaging Accessories & Consumables.

The post Trivitron’s Kiran Radiation Protection Products now comply with ISO’s Biocompatibility Quality Standards appeared first on Health Vision.